Basic information
Biomarker: MSI-H status
Biomarker subtype: gene
Clinical application: prognosis(unfavorable)
Histology type: endometrioid endometrial carcinoma
Stage: stage I
Cohort characteristics
Country: Norway
Region: Stavanger
Study type: retrospective study
Followed up time : 61 months median follow-up (1-209)
Cohort age: 102;99
Protocol age: 95;17
Control age: 78;21
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 273 | EC | 273 |
Sample information
Sample type : tissue
Clinical method: pentaplex polymerase chain,PCR-amplification
Expression pattern : High frequency
Expression elevation: Instability in 40% (2 of 5) of the markers was classified as high-frequency microsatellite instability (MSIH), in 1 of 5 markers as low-frequency (MSI-L), and in no markers as microsatellite stable (MSS). In line with other studies, MSI-L were grouped together with MSS cases for most analyses.
Disease information
Statictics: cutoff<68;cutoff>68
Cohort age: 102;99
Protocol age: 95;17
Control age: 78;21
Related information
Description: MSI-H status assessed by pentaplex polymerase chain reaction is an indicator of poor prognosis in FIGO 1, but not in FIGO 2-4 endometrial endometrioid adenocarcinomas.
Survival figure legend: Survival curve of the FIGO I endometrioid endometrial cancer patients
Survival curve link: https://www.nature.com/articles/modpathol201175/figures/1
Expression figure legend: Favorable combination of biomarkers p21.$ Unfavorable combination of biomarkers p21, survivin and microsatellite instability.
Expression figure link: https://www.nature.com/articles/modpathol201175/figures/2 $https://www.nature.com/articles/modpathol201175/figures/3
